Claudia Caserta

3.8k total citations · 1 hit paper
50 papers, 949 citations indexed

About

Claudia Caserta is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Claudia Caserta has authored 50 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 16 papers in Surgery. Recurrent topics in Claudia Caserta's work include Renal cell carcinoma treatment (17 papers), Bladder and Urothelial Cancer Treatments (15 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Claudia Caserta is often cited by papers focused on Renal cell carcinoma treatment (17 papers), Bladder and Urothelial Cancer Treatments (15 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Claudia Caserta collaborates with scholars based in Italy, United States and United Kingdom. Claudia Caserta's co-authors include F. Roila, Jeffrey Crawford, Sergio Bracarda, Petros Grivas, Se Hoon Park, Cora N. Sternberg, Alessandra di Pietro, Thomas Powles, Srikala S. Sridhar and Yohann Loriot and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Claudia Caserta

47 papers receiving 929 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

2023 118 citations Thomas Powles, Se Hoon Park et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Claudia Caserta

Since Specialization

Citations

This map shows the geographic impact of Claudia Caserta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Caserta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Caserta more than expected).

Fields of papers citing papers by Claudia Caserta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Caserta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Caserta. The network helps show where Claudia Caserta may publish in the future.

Co-authorship network of co-authors of Claudia Caserta

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Caserta. A scholar is included among the top collaborators of Claudia Caserta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Caserta. Claudia Caserta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study 2024 ·Clinical Genitourinary Cancer ·Annalisa Guida, Alessio Gili, Claudia Mosillo, Marco Maruzzo, (unknown), (unknown), (unknown), Umberto Basso, Giuseppe Fornarini, Sara Elena Rebuzzi, Fabio Calabrò, Linda Cerbone, Claudia Caserta, (unknown), (unknown), Orazio Caffo, Sarah Scagliarini, Sergio Bracarda	0
2	The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer 2024 ·Cancer Treatment Reviews ·Annalisa Guida, Claudia Mosillo, (unknown), Claudia Caserta, (unknown), Vincenza Conteduca, Sergio Bracarda	0
3	Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up breakdown → 2023 ·Journal of Clinical Oncology ·Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros Grivas	118
4	Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial 2023 ·European Urology ·Petros Grivas, Se Hoon Park, Éric Voog, Claudia Caserta, Howard Gurney, Joaquim Bellmunt, Haralabos P. Kalofonos, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Yoshiaki Yamamoto, Daniel P. Petrylak, Cora N. Sternberg, Shilpa Gupta, Bo Huang, Nuno Costa, Robert J Laliberte, Alessandra di Pietro, Begoña P. Valderrama, Thomas Powles	30
5	Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? 2021 ·Current Oncology Reports ·Ernesto Rossi, Melissa Bersanelli, Alain Gelibter, Nicolò Borsellino, Claudia Caserta, Laura Doni, Marco Maruzzo, Alessandra Mosca, Carmela Pisano, Elena Verzoni, Paolo Andrea Zucali	18
6	745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC) 2020 ·Annals of Oncology ·Thomas Powles, Evgeny Kopyltsov, (unknown), Francis Parnis, S.H. Park, Yasuhiro Yamamoto, Peter C.C. Fong, Christophe Tournigand, Miguel Á. Climent Durán, Aristotelis Bamias, Claudia Caserta, Jane Chang, (unknown), Alessandra di Pietro, (unknown), Petros Grivas	8
7	704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 2020 ·Annals of Oncology ·Petros Grivas, S.H. Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Shilpa Gupta, Bo Huang, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Thomas Powles	10
8	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study. 2020 ·Journal of Clinical Oncology ·Roberto Iacovelli, Sebastiano Buti, Consuelo Buttigliero, Rocco De Vivo, Claudia Caserta, Francesco Ferraù, Luca Galli, Valentino Martelli, Cristina Masini, Rodolfo Mattioli, Sara Merler, Laura Milesi, Emanuele Naglieri, Riccardo Ricotta, Mimma Rizzo, Cosimo Sacco, Daniele Santini, Rosa Tambaro, Elena Verri, Matteo Santoni	0
9	Toward a genome-based treatment landscape for renal cell carcinoma 2019 ·Critical Reviews in Oncology/Hematology ·Francesco Massari, Vincenzo Di Nunno, Matteo Santoni, Lidia Gatto, Claudia Caserta, Franco Morelli, Elena Zafarana, Francesco Carrozza, Alessandra Mosca, Veronica Mollica, Roberto Iacovelli, Roberto Sabbatini, Camillo Porta, Sergio Bracarda	14
10	Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience 2018 ·Anticancer Research ·Andrea Sbrana, Elisa Biasco, (unknown), (unknown), Claudia Caserta, Roberto Iacovelli, Beatrice Detti, Daniele Santini, Alessandra Mosca, Franco Morelli, Giuseppe Fornarini, Ugo De Giorgi, Cristina Masini, Luca Galli	3
11	Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP) 2017 ·Annals of Oncology ·Ugo De Giorgi, Giuseppe Procopio, Annalisa Guida, Alessandra Bearz, Sebastiano Buti, Umberto Basso, Manfred Mitterer, Cinzia Ortega, Paolo Bidoli, Francesco Ferraù, Lucio Crinò, Antonio Frassoldati, Paolo Marchetti, Enrico Mini, Alessandro Scoppola, Claudio Verusio, Giuseppe Fornarini, Giacomo Cartenì, Claudia Caserta, Cora N. Sternberg	3
12	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma 2016 ·Neuro-Oncology ·Alba A. Brandes, Gaetano Finocchiaro, Vittorina Zagonel, Michele Reni, Claudia Caserta, Alessandra Fabi, Matteo Clavarezza, Evaristo Maiello, Marica Eoli, Giuseppe Lombardi, Marta Monteforte, (unknown), R. Agati, Vincenzo Eusebi, Enrico Franceschi	61
13	Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) 2016 ·Annals of Oncology ·Nizar M. Tannir, Thomas Powles, Robert J. Motzer, Frédéric Rolland, Gwénaëlle Gravis, Michael Staehler, Michael Rink, Margitta Retz, Tibor Csőszi, John McCaffrey, Ugo De Giorgi, Claudia Caserta, Sergey Cheporov, Emilio Esteban, Ignacio Durán, James Larkin, William J. Berg, D O Clary, Bernard Escudier, Toni K. Choueiri	1
14	Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study 2015 ·Annals of Oncology ·Fausto Roila, Benedetta Ruggeri, Enzo Ballatori, Sonia Fatigoni, Claudia Caserta, Lisa Licitra, Aurora Mirabile, (unknown), B. Massidda, Luigi Cavanna, Maria Angela Palladino, Angelo Tocci, S. Fava, Ida Colantonio, Lucia Angelelli, L. Ciuffreda, Gianpiero Fasola, (unknown)	24
15	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY) 2012 ·European Urology ·Sergio Bracarda, Camillo Porta, C. Boni, Armando Santoro, Claudia Mucciarini, Antonio Pazzola, Enrico Cortesi, Donatello Gasparro, Roberto Labianca, Francesco Di Costanzo, Alfredo Falcone, Michela Cinquini, Claudia Caserta, Chiara Paglino, Verena De Angelis	21
16	Reirradiation of brain metastases with radiosurgery 2011 ·Radiotherapy and Oncology ·Ernesto Maranzano, Fabio Trippa, Michelina Casale, (unknown), Paola Anselmo, Sandro Carletti, (unknown), Claudia Caserta, (unknown), Cesare Giorgi	37
17	Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications 2010 ·Annals of Oncology ·Jeffrey Crawford, Claudia Caserta, F. Roila	165
18	Hematopoietic growth factors: ESMO Recommendations for the applications 2009 ·Annals of Oncology ·Jeffrey Crawford, Claudia Caserta, F. Roila	36
19	Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib 2007 ·Annals of Oncology ·Sergio Bracarda, Claudia Caserta, (unknown), Marta Rossi, (unknown), Lucio Crinò	26
20	Targeting of EGFR tyrosine kinase by ZD1839 (“Iressa”) in androgen-responsive prostate cancer in vitro 2006 ·Molecular Genetics and Metabolism ·Ilaria Bellezza, Sergio Bracarda, Claudia Caserta, Alba Minelli	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact